-
Gestational Polystyrene Nanoplastics and Male Reproduction
2026-09-19
This study integrates testicular transcriptomics, serum metabolomics, histopathology, and adverse outcome pathway modeling to examine how gestational polystyrene nano-plastics exposure impairs reproduction in adult male offspring. Its partial-AOP framework links altered arachidonic acid, reactive oxygen species, palmitic acid, and lysophosphatidylcholine biology with testicular injury and abnormal spermatogenesis, while also identifying cellular death as a mechanistic node that warrants targeted validation.
-
Halazone and Sodium Current Inactivation in Frog Fibers
2026-09-19
The reference study used a comparative chemical-reagent strategy to test whether methionine, histidine, tyrosine, arginine, or membrane lipids govern sodium-current inactivation in voltage-clamped frog nerve fibers. Halazone and hypochlorous acid produced unusually strong, nonstandard changes in inactivation, challenging a direct methionine-centered explanation and supporting a tentative membrane-lipid mechanism.
-
PGF2α/PTGFR and HIF-1α in Endometrial Breakdown
2026-09-18
A 2024 mouse menstrual-like model study identifies PGF2α/PTGFR as a functional regulator of endometrial breakdown and vascular permeability downstream of progesterone withdrawal. By combining receptor inhibition, tissue profiling, localization studies, and promoter-binding analysis, the work connects HIF-1α activity with PTGFR, VEGF-A, and angiostatin responses.
-
PTT and CD47 Blockade Synergy in OSCC
2026-09-18
A 2026 study shows that photothermal therapy (PTT) strengthens CD47 blockade in oral squamous cell carcinoma by generating a calreticulin-dependent phagocytic signal and reducing extracellular-matrix barriers to macrophage access. Its main contribution is a two-part mechanistic model linking tumor-cell immunogenic death with improved immune-cell proximity.
-
Protease Inhibitor Cocktail for MS Proteomics
2026-09-17
The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) supports protein degradation prevention during cell and tissue extraction. Its AEBSF-free formulation is designed for mass spectrometry workflows, while its inhibitor blend covers cysteine, serine, acid proteases, and aminopeptidases.
-
AL-8810: Translating FP Receptor Biology
2026-09-17
A translational perspective on how AL-8810, a selective prostaglandin F2α antagonist, can help researchers separate FP receptor signaling from downstream vascular, smooth-muscle, ERK1/2, and MMP-2 responses. The article connects recent endometrial biology with practical experimental design while defining the limits of preclinical interpretation.
-
AL-8810: Prostaglandin F2α Antagonist Guide
2026-09-16
AL-8810 is a reversible prostaglandin F2α antagonist for separating FP receptor signaling from downstream vascular, smooth-muscle, ERK1/2, and MMP-2 responses. This workflow translates recent endometrial research into practical concentration-selection, control, readout, and troubleshooting strategies.
-
Acifran: Practical HCAR Signaling Workflows
2026-09-15
Build more interpretable lipid-receptor experiments with Acifran, from controlled cAMP assays to receptor-comparison studies. This workflow combines structural evidence, compound-handling guidance, and troubleshooting for lipid metabolism regulation research.
-
Bufalin: From Cardiotonic Steroid to Targeted Degrader
2026-09-15
Bufalin is moving from a broadly active cardiotonic steroid to a mechanistically testable oncology research tool. This article examines its apoptosis and differentiation biology, emerging STK33 degradation mechanism in triple-negative breast cancer, translational validation strategy, and the boundaries that researchers must address before clinical interpretation.
-
Atorvastatin Beyond Lipid Lowering: A Translational Playbook
2026-09-14
Atorvastatin is more than a cholesterol biosynthesis inhibitor. By perturbing the mevalonate pathway, it offers translational researchers a way to connect lipid flux, Ras and Rho signaling, vascular stress, and ferroptosis. This article interprets recent hepatocellular carcinoma evidence alongside cardiovascular models and presents a practical framework for designing, validating, and responsibly advancing Atorvastatin-based research hypotheses.
-
Cisapride (R 51619) in iPSC-CM Assay Design
2026-09-14
Cisapride (R 51619) connects hERG channel inhibition and 5-HT4 receptor pharmacology with modern cardiotoxicity screening. This guide translates deep-learning high-content imaging into practical assay-design decisions for cardiac electrophysiology research.
-
PDK4-IN-1 Hydrochloride: From Mechanism to Translation
2026-09-13
PDK4-IN-1 hydrochloride offers a selective way to investigate PDH activation, mitochondrial energy metabolism modulation, and glycolysis–TCA cycle regulation. This thought-leadership analysis connects the compound’s biochemical rationale with assay design, disease-model strategy, competitive positioning, and translational limitations.
-
L-Phenylephrine in α1A Receptor Research
2026-09-12
L-Phenylephrine is an adrenergic α1A receptor agonist for separating receptor-driven responses from broader cardiovascular stress signals. This practical guide connects sex-aware telemetry, cardiomyocyte assays, neural progenitor studies, and troubleshooting strategies while keeping acute receptor challenges distinct from chronic angiotensin II models.
-
LMP2A–mTORC1–GCNT3 Signaling in Nasopharyngeal Carcinoma
2026-09-12
The 2024 Virus Genes study identifies an LMP2A–mTORC1–GCNT3 regulatory axis in nasopharyngeal carcinoma, linking Epstein–Barr virus latency to glycosylation, epithelial–mesenchymal transition, migration, and proliferation. Its pathway-ordering experiments suggest that GCNT3 is both an mTORC1-responsive effector and a contributor to positive feedback, while the GCNT3–ZEB1 interaction provides a mechanistic explanation for enhanced cell motility.
-
Masitinib (AB1010): KIT/PDGFR Assay Guide
2026-09-11
Masitinib (AB1010) is a DMSO-compatible tyrosine kinase inhibitor for research involving KIT, PDGFRα, PDGFRβ, mast-cell responses, and selected GIST models. It is useful for controlled in vitro and in vivo study design, but should not be used in aqueous or ethanol-based workflows, assumed to be broad-spectrum, or treated as clinical evidence without independent validation.